1 Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Fl, Boston, MA 02114.
AJR Am J Roentgenol. 2015 Jun;204(6):1228-33. doi: 10.2214/AJR.14.13287.
Patients with limited-stage Hodgkin lymphoma (HL) undergo frequent posttreatment surveillance CT examinations, raising concerns about the cumulative magnitude of radiation exposure. The purpose of this study was to project radiation-induced cancer risks relative to competing risks of HL and account for the differential timing of each.
We adapted a previously developed Markov model to project lifetime mortality risks and life expectancy losses due to HL versus radiation-induced cancers in HL patients undergoing surveillance CT. In the base case, we modeled 35-year-old men and women undergoing seven CT examinations of the chest, abdomen, and pelvis over 5 years. Radiation-induced cancer risks and deaths for 17 organ systems were modeled using an organ-specific approach, accounting for specific anatomy exposed at CT. Cohorts of 20-, 50-, and 65-year-old men and women were evaluated in secondary analyses. Markov chain Monte Carlo methods were used to estimate the uncertainty of radiation risk projections.
For 35-year-old adults, we projected 3324/100,000 (men) and 3345/100,000 (women) deaths from recurrent lymphoma and 245/100,000 (men, 95% uncertainty interval [UI]: 121-369) and 317/100,000 (women, 95% UI: 202-432) radiation-induced cancer deaths. Discrepancies in life expectancy losses between HL (428 days in men, 482 days in women) and radiation-induced cancers (11.6 days in men, [95% UI: 5.7-17.5], 15.6 days in women [95% UI: 9.8-21.4]) were proportionately greater because of the delayed timing of radiation-induced cancers relative to recurrent HL. Deaths and life expectancy losses from radiation-induced cancers were highest in the youngest cohorts.
Given the low rate of radiation-induced cancer deaths associated with CT surveillance, modest CT benefits would justify its use in patients with limited-stage HL.
局限性霍奇金淋巴瘤(HL)患者在接受治疗后需要进行频繁的随访 CT 检查,这引发了对累积辐射暴露量的担忧。本研究旨在预测与 HL 相关的放射诱导性癌症风险,并考虑到每种风险的不同时间。
我们采用了之前开发的马尔可夫模型,对接受 CT 监测的 HL 患者进行了终生 HL 死亡率和因 HL 或放射诱导性癌症而导致的预期寿命损失的预测。在基础情况下,我们对 35 岁的男性和女性进行了建模,这些患者在 5 年内进行了 7 次胸部、腹部和骨盆的 CT 检查。采用特定器官的方法对 17 个器官系统的放射诱导性癌症风险和死亡进行建模,考虑了 CT 暴露的特定解剖结构。在二次分析中评估了 20 岁、50 岁和 65 岁的男性和女性队列。采用马尔可夫链蒙特卡罗方法来估计放射风险预测的不确定性。
对于 35 岁的成年人,我们预计会有 3324/100000(男性)和 3345/100000(女性)死于复发性淋巴瘤,以及 245/100000(男性,95%置信区间[UI]:121-369)和 317/100000(女性,95% UI:202-432)的放射诱导性癌症死亡。HL(男性 428 天,女性 482 天)和放射诱导性癌症(男性 11.6 天,[95% UI:5.7-17.5],女性 15.6 天,[95% UI:9.8-21.4])之间预期寿命损失的差异是不成比例的,这是因为放射诱导性癌症相对于复发性 HL 的时间延迟。在最年轻的队列中,放射诱导性癌症的死亡和预期寿命损失最高。
鉴于 CT 监测相关的放射诱导性癌症死亡发生率较低,适度的 CT 获益将使其在局限性 HL 患者中使用合理化。